The company's lead program, REL-1017, is a novel NMDA receptor channel blocker being developed as an oral treatment for major depressive disorder. Relmada Therapeutics aims to make a difference in the lives of patients and their families by addressing areas of high unmet medical need in the treatment of CNS diseases.